Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Intellia Therapeutics (NASDAQ:NTLA) will present at the 44th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Intellia Therapeutics (NASDAQ:NTLA) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2026 at 9:00 a.m. PT. A live webcast will be available on the company’s Events and Presentations page in the Investors & Media section at www.intelliatx.com. A replay of the webcast will be available on the website for approximately 30 days after the presentation.
Details
News Market Reaction – NTLA
On Jan 7, the day this news came out, NTLA closed 4.11% above the previous close.
Data tracked by StockTitan Argus for the Jan 7 session.
Key Figures
- Conference date
- January 14, 2026
- Scheduled J.P. Morgan Healthcare Conference presentation
- Presentation time
- 9:00 a.m. PT
- Start time of J.P. Morgan presentation webcast
- Webcast replay duration
- 30 days
- Replay available on company website
Historical Context
-
Announcement of 22,800 RSU inducement grants for two new employees.
-
Equity awards totaling 12,600 RSUs to three new employees under inducement plan.
-
Longer-term Phase 1 data for nex-z in ATTR cardiomyopathy showing durable TTR reduction.
-
Pooled Phase 1/2 HAE data for lonvo-z with high attack-free and LTP-free rates.
-
Q3 2025 loss and disclosure of FDA clinical hold on Phase 3 MAGNITUDE trials.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
CRISPR medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 9:00 a.m. PT.
A live webcast will be available on the Events and Presentations page in the Investors & Media section of Intellia’s website, www.intelliatx.com. A replay of the webcast will be available on Intellia’s website for approximately 30 days.
About Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.
Intellia Contacts:
Investors:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
jason.fredette@intelliatx.com
Media:
Matt Crenson
Ten Bridge Communications
media@intelliatx.com
mcrenson@tenbridgecommunications.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.